Myostatin Serum Related with Sarcopenia Among Elderly Population

Authors

  • Ronald Winardi Kartika Departemen Bedah FKIK UKRIDA Program Studi Magister Biomedik FKIK Atma Jaya Jakarta, Indonesia

DOI:

https://doi.org/10.21460/bikdw.v7i2.530

Keywords:

myostatin, katabolic sarcopenia, elderly

Abstract

Background Sarcopenia is a decrease in muscle mass accompanied by a decrease in muscle strength and performance. Sarcopenia arises from a disturbance of the complex balance between anabolic and catabolic factors. Myostatin strongly influences the inhibition of muscle growth by increasing muscle catabolism. Increased myostatin will atrophy in skeletal muscle. In the aging process, there will be an increase in the hormone myostatin plays an active role in the process of sarcopenia. The cause of the increase in myostatin hormone is a chronic inflammatory process that occurs in the aging process.Methods The writing of this paper is a literature review of the role of myostatin in sarcopenia that occurs due to the aging process.Results The incidence of sarcopenia in the elderly was 45 people (64.3%). The results of the analysis were a significant difference between myostatin levels in sarcopenia (47.59 ng/mL) and non-sarcopenia (39.7 ng/mL) subjects. The limit of myostatin levels that can cause an increase in muscle catabolic processes is 48.91 ng/mL. The prevalence ratio of the incidence of sarcopenia based on myostatin levels in the elderly was 3.84, while based on the combined risk of age and myostatin levels was 9.75.Conclusion From the literature review, it was found that there was a significant difference in myostatin levels between the elderly with and without sarcopenia. The prevalence of high myostatin levels in the elderly is almost 4 times higher than in young adults. This will lead to the progression of sarcopenia.

References

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.

Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300-307.

Ran Zalk, Oliver B. Clarke, Amédée des Georges, Robert A. Grassucci, Steven Reiken, Filippo Mancia, Wayne A. Hendrickson, Joachim Frank, Andrew R. Marks. Structure of a mammalian ryanodine receptor. Nature, 2014; 517 (7532): 44 -49

Joachim Frank et al. Structural Basis for Gating and Activation of RyR1. Cell, September 2016

Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Sarcopenia: an overview. Aging Clin Exp Res. 2017;29(1):11–7.

Rodríguez-Rejón AI, Ruiz-López MD, Wanden-Berghe C, Artacho R. Prevalence and Diagnosis of Sarcopenia in Residential Facilities: A Systematic Review. Adv Nutr. 2019;10(1):51–8

Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3β pathway and is antagonized by insulin-like growth factor. J Biol Chem. 2007; 282: 3799-808.

Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol. 2009; 296:C1248-57.

Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. AJP Cell Physiol. 2009; 296: 1258-70.

Murbawani EA, Puruhita N, Yudomurti. Tinggi badan yang diukur dan berdasarkan tinggi lutut menggunakan rumus Chumlea pada lansia. Med Med Indones. 2012; 49: 1-6.

Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc. 2014; 15: 95-101.

Vitriana, Defi IR, Irawan GN, Setiabudiawan B. Prevalensisarkopenia pada lansia di komunitas (Community Dwelling) berdasarkan dua nilai cut-off parameter diagnosis. Maj Kedokt Bandung. 2016; 48: 164-70.

Limpawattana P, Kotruchin P, Pongchaiyakul C. Sarcopenia in Asia. Osteoporos Sarcopenia. 2015; 1: 92-7.

Gao L, Jiang J, Yang M, Hao Q, Luo L, Dong B. Prevalence of sarcopenia and associated factors in Chinese community-dwelling elderly: comparison between rural and urban areas. J Am Med Dir Assoc. 2015; 16: 1003.e1-e6.

Messier V, Rabasa-lhoret R, Barbat-artigas S, Elisha B, Karelis AD, Aubertin-leheudre M. Menopause and sarcopenia: a potential role for sex hormones. Maturitas. 2011; 68: 331-6.

Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci. 1993; 84: 95-8.

Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 147: 755-63.

Fried LP, Walston JD, Ferrucci L. Frailty. In: Geriatric Medicine. 6th ed. Berlin: Springer-Verlag; 2009. p.1067–76.

Bergen HR, Farr JN, Vanderboom PM, Atkinson EJ, White TA, Singh RJ, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: Insights using a new mass spectrometrybased assay. Skelet Muscle. 2015; 5: 21.

Siriett V, Platt L, Salerno MS, Ling N, Kambadur R, Sharma M. Prolonged absence of myostatin reduces sarcopenia. J Cell Physiol. 2006; 209: 866-73.

Camporez JG, Petersen MC, Abudukadier A, Moreira G V, Jurczak MJ, Friedman G, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci USA.2016; 113: 2212-7.

Peng LN, Lee WJ, Liu LK, Lin MH, Chen LK. Healthy communityliving older men differ from women in associations between myostatin levels and skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2018; 9: 635-42.

Elkina Y, Haehling S Von, Anker SD. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011; 2: 143-51.

Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem. 2008;283:19371–19378

M.J. Schafer, E.J. Atkinson, P.M. Vanderboom, B. Kotajarvi, T.A. White, M.M. Moore, et al. The clinical impact and biological mechanisms of skeletal muscle aging Cell Metab., 23 (2016), pp. 1207-1215

Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel. 2008;11:487–494

Downloads

Published

2022-12-20

Issue

Vol. 7 No. 2 (2022): BERKALA ILMIAH KEDOKTERAN DUTA WACANA

Section

Review

Citation Check

License

Authors who publish in Berkala Ilmiah Kedokteran Duta Wacana agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

This work is licensed under CC BY-SA 4.0